Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
molecular docking and dynamic simulation of anti-cholinesterase compounds from the extract of for possible treatment of Alzheimer's disease.
Heliyon
April 2024
Department of Pharmacognosy, Sri Shanmugha College of Pharmacy, Salem district, Sankari, 637 304, Tamil Nadu, India.
Alzheimer's disease (AD), is characterized by a progressive loss of cognitive abilities as well as behavioral symptoms including disorientation, trouble solving problems, personality and mood changes. Acetylcholinesterase (AChE) is a promising target for symptomatic improvement in AD due to its consistent and early cholinergic deficit. This research has investigated the potential compounds from as AChE inhibitors as a treatment option for AD, aiming to enhance cholinergic neurotransmission and alleviate cognitive decline.
View Article and Find Full Text PDFEvidence of Accidental Dosing Errors with Immediate-Release Sodium Oxybate: Data from the US Food and Drug Administration Adverse Event Reporting System.
Drugs Real World Outcomes
June 2023
Avadel Pharmaceuticals, Medical and Clinical Affairs, Chesterfield, MO, USA.
Introduction: Sodium oxybate has been approved by the US Food and Drug Administration (FDA) to treat narcolepsy for 20 years; however, the only available products have been immediate-release (IR) formulations given twice nightly-once at bedtime and a second dose 2.5-4 h later-creating inherent risks with dosing administration errors.
Objectives: Evidence and risks associated with accidental ingestion of the second IR oxybate dose < 2.
Unraveling the Gordian knot: genetics and the troubled road to effective therapeutics for Alzheimer's disease.
Genetics
January 2022
Department of Neurology, University of Arizona Health Sciences, Tucson, AZ 85724, USA.
In the late 20th century, identification of the major protein components of amyloid plaques and neurofibrillary tangles provided a window into the molecular pathology of Alzheimer's disease, ushering in an era of optimism that targeted therapeutics would soon follow. The amyloid-cascade hypothesis took hold very early, supported by discoveries that dominant mutations in APP, PSEN1, and PSEN2 cause the very rare, early-onset, familial forms of the disease. However, in the past decade, a stunning series of failed Phase-3 clinical trials, testing anti-amyloid antibodies or processing-enzyme inhibitors, prompts the question, What went wrong? The FDA's recent controversial approval of aducanumab, despite widespread concerns about efficacy and safety, only amplifies the question.
View Article and Find Full Text PDFThe Conundrum of Online Prescription Drug Promotion Comment on "Trouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: A Content Analysis of FDA Warning Letters".
Int J Health Policy Manag
March 2016
Moffort College of Business, University of Northern Colorado, Greeley, CO, USA.
This commentary discusses pertinent issues from Hyosun Kim's paper on online prescription drug promotion. The study is well-designed and the findings highlight some of the consequences of the Food and Drug Administration's (FDA's) decision to deregulate online advertising of prescription drugs. While Kim's findings confirm some of the early concerns, they also provide a perspective of implementation challenges in the ever-changing technological environment.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!